Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Apr 3, 2014- Company to Present Data on SF3B1 Program at a Symposium During the American Association for Cancer Research Annual Meeting 2014 -
H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision medicines for oncology, announced today...
-
Mar 31, 2014
Eisai Inc., a subsidiary of Tokyo-based Eisai Co., Ltd., today announced the sale and assignment of its rights to a worldwide exclusive license...
-
Mar 20, 2014JOINT RESEARCH PROJECT AWARDED GHIT FUND GRANT
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has entered a collaboration with the Liverpool School...
-
Mar 17, 2014Eisai Supports Epilepsy Foundation as Sponsor of Walk
Eisai Inc. announced today that it is a sponsor of the Epilepsy Foundation's 8th Annual National Walk for Epilepsy in Washington D.C., a...
-
Mar 13, 2014Sisters Network® Inc. launches innovative pilot program designed to help address breast cancer disparities affecting the African American community
Sisters Network, the only national African American breast cancer survivorship organization, announced today the launch of Teens 4...
-
Mar 10, 2014Company Appoints New Executive Leaders
Eisai Inc., a subsidiary of Tokyo-based Eisai Co., Ltd., today announced the appointments of Yuji Matsue as chairman and chief executive...
-
Feb 27, 2014Patient Recruitment Now Underway at Treatment Centers Across the United States
Eisai Inc. today announced the start of a large, randomized Phase 3 trial to compare the efficacy, safety and tolerability of eribulin mesylate...
-
Feb 24, 2014Patient Recruitment and Enrollment Now Underway
Eisai Inc. today announced that patient recruitment and enrollment are currently underway for CAMELLIA-TIMI 61, a randomized double-blind,...
-
Feb 12, 2014
Eisai Inc. announced today that its subsidiary Eisai Laboratorios Ltda has filed for the marketing authorization of BELVIQ as a treatment for...
-
Feb 10, 2014Number of Insured Commercial Lives in the U.S. with Coverage for BELVIQ® Now Exceeds 50 Percent
Eisai Inc. reported today that it has secured improved patient access of BELVIQ® (lorcaserin HCl) with two leading healthcare benefit...
